Matt Manning, Chair, Clinical Liaison Council at Fuse Oncology, shared on LinkedIn:
“Is 88.6% disease-free survival at 3 years acceptable for curable intermediate-risk prostate cancer in 2026?
NRG-GU005 is now published in JAMA: 3-year DFS was 88.6% with SBRT vs 92.1% with IMRT.
Convenience matters. But so does cure. If we hypothesize we need higher dose SBRT, will we test that hypothesis in the next trial.”
Title: Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer, A Randomized Clinical Trial
Authors: Rodney J. Ellis, Stephanie L. Pugh, James B. Yu, Felix Y. Feng, Andre A. Konski, Robert L. Grubb III, Robert E. Wallace, David J. Gladstone, Cynthia Ménard, Joseph A. Miccio, Arthur J. Frazier, J. Daniel Pennington, Jeff M. Michalski, Daniel E. Spratt, Alvaro Martinez, Scott C. Morgan, Alina Mihai, Abhishek Ashok Solanki, Asim Amjad, Michael W. Straza, Guila Delouya, Thomas M. Schroeder, David T. Marshall, Nirav Kapadia, Akshar N. Patel, Terrence P. Cescon, Ali El-Gayed, Harold A. Yoon, Rebecca Paulus, Howard M. Sandler